Reversal of ABCB1- and ABCG2-mediated MDR byerlotinib (tarceva, OSI-774)

zhi shi,xingxiang peng,inwha kim,suneet shukla,qiusheng si,robert w robey,susan e bates,sirong wang,christine chim,tong shen,amit k tiwari,charles r ashby,liwu fu,suresh v ambudkar,zhesheng chen

IF: 11.2

2008-01-01

Cancer Research

Abstract:AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA 3247 It has been reported that gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has the ability to modulate the function of certain ATP-binding cassette (ABC) transporters and to reverse ABCB1 (P-gp)- and ABCG2 (BCRP/MXR)-mediated multidrug resistance (MDR) in cancer cells. However, it is unkonwn whether other EGFR TKIs have effects similar to that of gefitinib. In the present study, we have investigated the interaction of another EGFR TKI erlotinib with selected ABC drug transporters. Our findings show that erlotinib significantly potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation of paclitaxel or mitoxantrone in ABCB1 or ABCG2 overexpressing cells. Furthermore, erlotinib did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in all cells and was unable to reverse MRP1-mediated MDR and had no effect on the parental cells. Meanwhile, erlotinib remarkably inhibited the transport of E217βG and methotrexate by ABCG2. In addition, the results of ATPase assays show that erlotinib stimulated the ATPase activity of both ABCB1 and ABCG2. Interestingly, erlotinib slightly inhibited the photolabeling of ABCB1 with [125I]Iodoarylazidoprazosin at high concentration, but it did not inhibit the photolabeling of ABCG2 with [125I]Iodoarylazidoprazosin. Overall, we conclude that erlotinib reverses ABCB1- and ABCG2-mediated MDR in cancer cells through direct inhibition of the drug efflux function of ABCB1 and ABCG2. These findings may be useful for cancer combinational therapy with erlotinib in clinic.